about
A 40-month multicentre, randomised placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA projectBlau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes.Association of the microsatellite in the 3' untranslated region of the CD154 gene with rheumatoid arthritis in females from a Spanish cohort: a case-control study.Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activityLongitudinal practice patterns of prophylaxis of glucocorticoid-induced osteoporosis in patients with polymyalgia rheumatica.Factors associated with the intensification of treatment in rheumatoid arthritis in clinical practice.The teaching of rheumatology at the University. The journey from teacher based to student-centered learning.Intercentre variance in patient reported outcomes is lower than objective rheumatoid arthritis activity measures: a cross-sectional study.Two-year adherence to treatment and associated factors in a fracture liaison service in Spain.Fibromyalgia in patients with rheumatoid arthritis is associated with higher scores of disability.Interleukin-10 promoter polymorphisms in patients with systemic lupus erythematosus from the Canary Islands.[Application of guidelines for secondary prevention of fracture and the FRAX index in patients with fragility fracture].Reducing developmental risk for emotional/behavioral problems: a randomized controlled trial examining the Tools for Getting Along curriculum.Clinical and immunogenetic factors associated with pneumonia in patients with systemic lupus erythematosus: a case-control study.Preventing future fractures: effectiveness of an orthogeriatric fracture liaison service compared to an outpatient fracture liaison service and the standard management in patients with hip fracture.Blau Syndrome-Associated Uveitis: Preliminary Results From an International Prospective Interventional Case Series.Recommendations for the use of methotrexate in psoriatic arthritis.Results of a model of secondary prevention for osteoporotic fracture coordinated by rheumatology and focused on the nurse and primary care physicians.Results of a specific smoking cessation program for patients with arthritis in a rheumatology clinic.S100A12 and S100A8/9 proteins are biomarkers of articular disease activity in Blau syndrome.Androgen deprivation in prostate cancer and the long-term risk of fracture.Pustuloderma during cutaneous lupus treatment with thalidomideAdvice by the rheumatologist on quitting smoking: are we doing well with smokers?Secondary prevention program for osteoporotic fractures and long-term adherence to bisphosphonates[Spanish FRAX(®): pathing the way through walking]Kienböck Disease With Ultrasonographic Findings of Wrist ArthritisImpact of the implementation of a Fracture Liaison Service on pharmaceutical expenses for osteoporosis compared to an area without an FLSCardiovascular disease in the QUEST-RA study, 10 years later
P50
Q35249579-0661C44D-DF1D-445B-9ECE-DCFAC5D2EE83Q35443835-68564421-3ABD-437A-8BB9-E48D588D4B10Q36401891-238C2182-50E7-4D32-8616-0A5258D0D57BQ36990607-E9AF4E0F-F180-4CBC-B85C-503272A1E87DQ38204240-98DB4551-9CFC-4C8D-9C4C-C59B0E202AD9Q38559816-1045B535-2374-482D-9BBC-90F8FE313C96Q38562444-3D71CC2F-8235-4F21-B4D8-E383D1E4A8AAQ38748219-E32C8037-A121-4F1D-8A9E-FB2DCDD3E6F9Q40863939-17D5859A-EF4D-42DE-80DC-62A6213A39A5Q42719027-E2DDE6D8-9100-41A2-B01D-19A2B8114218Q44414243-401EB35C-3B66-41C3-B540-90AE57916D7CQ44958172-FB8E0578-6133-469E-9773-1A9CAE8322C1Q44999103-9EDE0FAF-E444-4CAC-961F-20F593132F26Q45892795-808601C5-1B0A-4A5B-8872-FEB5A7C7944EQ47326154-CC1253C4-E00C-45AE-AD5D-5988F0621B18Q48011327-A423F377-5735-4ED8-BC29-705148F4C370Q50098914-2C2962EF-8033-4C91-9D2F-36BF68677DF1Q51159166-4EE782AD-8C55-4BCB-9266-24F51D2C2DDAQ51224150-D3AC5D86-5437-4F25-BC41-5FCD89FB98B8Q52720267-4FCDD32D-9C8E-41E5-802B-7833CDA404C0Q53464683-1256898B-6100-4A74-9EF8-CBAC897701E0Q77794870-B2825453-1ED6-490A-B2E0-9494D996974FQ83714904-2721DD1B-27B6-45C0-97B9-1091BDDF263AQ85161387-17EFCF36-AD36-4A04-917F-F39D0F1FEF0BQ87442864-CBF79BBD-9041-45C9-8137-8E430C3C4EC0Q88052066-364B4A85-148D-4E56-AAC9-18C35B0EE43BQ91058743-57EB252B-0524-4873-90F9-B906F3096875Q91284221-39A8B706-0AEE-4FF1-A748-C0CA42E68251
P50
description
researcher ORCID ID = 0000-0002-2013-6664
@en
wetenschapper
@nl
name
Antonio Naranjo Hernández
@ast
Antonio Naranjo Hernández
@en
Antonio Naranjo Hernández
@es
Antonio Naranjo Hernández
@nl
type
label
Antonio Naranjo Hernández
@ast
Antonio Naranjo Hernández
@en
Antonio Naranjo Hernández
@es
Antonio Naranjo Hernández
@nl
prefLabel
Antonio Naranjo Hernández
@ast
Antonio Naranjo Hernández
@en
Antonio Naranjo Hernández
@es
Antonio Naranjo Hernández
@nl
P108
P108
P21
P31
P496
0000-0002-2013-6664